Pramiracetam
From Wikipedia, the free encyclopedia
 |
|
 |
|
|
Pramiracetam
|
|
| Systematic (IUPAC) name | |
| N-[2-(dipropan-2-ylamino)ethyl]-2-(2-oxopyrrolidin-1-yl)acetamide | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C14H27N3O2 |
| Mol. mass | 269.383 g/mol |
| SMILES | & |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 4.5-6.5 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
Unscheduled (US) |
| Routes | Oral |
Pramiracetam is a nootropic drug derived from piracetam, and is more potent (i.e. lower dosage is used). It belongs to the racetam family of nootropics.
Pramiracetam was developed by Parke-Davis based on Piracetam, and is 8-30 times stronger than Piracetam. It goes by the trade name Neupramir or Pramistar.
[edit] External links
|
|||||
|
|||||||||||||||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
